Synaptiflora

Company Overview

Snapshot

Founded in September 2024 by Shaul Sapielkin, Synaptiflora operates with 1–10 employees. The company has raised $10,000 across one funding round. In September 2025, Synaptiflora was recognized as a top AI drug discovery company by StartUs Insights.

Business overview

Synaptiflora is an AI-powered microbiome intelligence platform that analyzes and predicts how the human microbiome influences drug response, disease biology, and product performance. Its core technology combines strain-level microbiome indexing, a proprietary ex vivo high-throughput screening system, and machine-learning models trained on extensive human microbiome datasets. The company primarily serves the pharmaceutical R&D sector, aiming to improve clinical trial success, patient stratification, and drug efficacy, with applications also extending to nutrition, cosmetics, and agriculture for microbiome-aware product design.

Strategic signal

In September 2025, Synaptiflora was featured by StartUs Insights as one of the top AI drug discovery companies. This recognition highlights the company's innovative approach to leveraging AI and microbiome intelligence to enhance pharmaceutical R&D, signaling its potential as a key player in advancing precision medicine and drug development.

Company Intelligence Q&A

When was Synaptiflora founded?

Synaptiflora was founded in September 2024.

Who is a founder of Synaptiflora?

Shaul Sapielkin is a founder of Synaptiflora.

What is Synaptiflora's primary focus?

Synaptiflora focuses on pharmaceutical R&D, helping partners improve clinical trial success, patient stratification, and drug efficacy by accounting for microbiome-driven variability.

What was a significant recognition for Synaptiflora?

In September 2025, Synaptiflora was recognized by StartUs Insights as one of the top AI drug discovery companies.

What is Synaptiflora's total funding?

Synaptiflora has raised a total of $10,000 across one funding round. This funding was secured prior to October 2024.